Gregory Scott Duncan
Gregory Scott Duncan's purchase track record
How the stock did after each of Gregory Scott Duncan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/17/2023 | DWTX | $31K | -39.2% | -67.8% | +15.1% |
| 5/23/2022 | DWTX | $34K | +45.5% | -92.9% | -0.6% |
| 12/21/2021 | DWTX | $28K | -4.8% | -26.5% | -19.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Dogwood to Join 2026 Maxim Growth Summit. Dogwood Therapeutics announced it will participate in the 2026 Maxim Growth Summit. The event is aimed at showcasing companies to investors and partners. Participation may raise the company’s profile and provide networking opportunities. The announcement comes as the stock trades near its 14‑touch support level.
Transaction History
| CRMD | ▲ Buy | Grant | 30,453 | $0 | 1/26/2026 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 13,333 | $111K | 9/16/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 25,000 | $0 | 1/17/2025 | View on chart |
| DWTX | ▲ Buy | Open Market | 25,000 | $31K | 8/17/2023 | View on chart |
| DWTX | ▲ Buy | Open Market | 7,500 | $34K | 5/23/2022 | View on chart |
| DWTX | ▲ Buy | Open Market | 5,000 | $28K | 12/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.